Table 1 Patients demographics and baseline disease characteristics
From: Primary central nervous system tumors in patients with multiple sclerosis
Variable | Patients with ptCNS (n = 36) | Patients without ptCNS (n = 2244) | p-value |
|---|---|---|---|
Age (mean ± SD)  At MS onset  At tumor diagnosis (mean ± SD) | 31.47 ± 9.10 45.47 ± 8.08 | 29.18 ± 8.96 -- | 0.13 |
Sex (n,%)  Male  Female | 1 (2.8%) 35 (97.2%) | 309 (13.8%) 1935 (86.2%) | 0.056 |
Type of MS (n,%)  RRMS  SPMS  PPMS | 35 (97.2%) 1 (2.8%) 0 (0) | 1980 (88.20%) 188 (8.40%) 76 (3.40%) | 0.23 |
Type of Medication (n,%)  INF beta-1a  INF beta-1b  Rituximab  Glatiramer Acetate  Dimethyl Fumarate  Fingolimod  Teriflunomide | 22 (61.1%) 5 (13.9%) 3 (8.3%) 1 (2.8%) 3 (8.3%) 1 (2.8%) 1 (2.8%) | 351 (18.3%) 239 (12.4%) 344 (17.9%) 63 (3.3%) 514 (26.7%) 209 (10.9%) 202 (10.5%) | < 0.001 |